Esperion Therapeutis.Inc. buy El_Zocko
Start price
29.09.15
/
50%
€20.64
Target price
20.10.16
€35.00
Performance (%)
-47.70%
End price
20.10.16
€10.79
Summary
This prediction ended on 20.10.16 with a price of €10.79. Massive losses of -47.70% were the result for the BUY prediction by El_Zocko. El_Zocko has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | 0.000% | 0.000% | 57.643% | 84.600% |
| iShares Core DAX® | 0.437% | 5.897% | 8.047% | 65.579% |
| iShares Nasdaq 100 | 1.057% | 0.920% | 28.466% | 90.185% |
| iShares Nikkei 225® | 1.769% | 1.228% | 47.574% | 84.991% |
| iShares S&P 500 | 0.368% | 1.920% | 23.200% | 70.760% |
Comments by El_Zocko for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Schlimmer geht nimmer?
Hoffen wir es!!
(Laufzeit überschritten)